With its minimum viable product (MVP) release on schedule and on budget, MINDCURE will work with its clinical partners to refine the application before full commercial deployment in Q1 2022. VANCOUVER, BC, Aug. 26, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics…


Previous articleClinical Director of Imperial College’s Center for Psychedelic Research Joins Entheon Advisory Board
Next articleMYND Life Sciences Announces $3 Million Convertible Debenture Unit Offering